CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED
Exhibit 10.6
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED
September 3, 2020
Xx. Xxxx Xxxxxxx
Co-founder and COO
0000 Xxxxxxx Xxx, Xxx 000
Xxxxxxx, Xxxxxxxx XXX 00000
RE: Letter Agreement Concerning [***]
(“[***] Letter Agreement”)
Dear Andy,
As you know, Brickell Biotech, Inc. (“Brickell”) and Kaken Pharmaceutical Co., Ltd. (“Kaken”) exchanged numerous emails and had a series of discussions concerning the [***] (as such term is defined in Schedule A attached hereto).
The purpose of this [***] Letter Agreement is to document the agreement reached by Brickell and Kaken through the exchange of emails and discussions regarding the [***] and certain related matters so as to avoid any misunderstanding between Brickell and Kaken. Accordingly, Brickell and Kaken hereby confirm and set forth their agreement regarding the [***] and certain related matters as follows:
1.The [***] shall be “[***]” for purposes of the License, Development and Commercialization Agreement entered into between Brickell and Kaken as of March 31, 2015, as amended (“LDCA”) and specifically pursuant to Section [***] of the LDCA, subject to the terms set forth in this [***] Letter Agreement.
2.Notwithstanding Section [***] of the LDCA:
a.Kaken [***], including [***] in [***] of the Kaken Territory (as such term is defined in the LDCA): [***] and [***] for the following countries of the Kaken Territory: [***], with all such [***] listing Kaken as [***], at Kaken’s [***] cost and expense; and
x.Xxxxxxxx [***], including [***] outside the Kaken Territory, with the [***] Brickell as [***], at Brickell’s [***] cost and expense.
3.No later than [***] prior to [***] for the [***], Kaken and Brickell shall inform each other [***] and [***] that they will [***] for the [***] in accordance with Paragraph 2(a) and Paragraph 2(b) of this [***] Letter Agreement.
4.Promptly after the date of this [***] Letter Agreement, Brickell and
Kaken will discuss in good faith the [***], obtaining necessary [***] to ensure that each of Brickell and Kaken have the rights to the [***] as set forth herein.
5.Except as expressly amended by this [***] Letter Agreement, the LDCA will remain in full force and effect.
Please kindly signify Brickell’s agreement to the foregoing terms by signing below where indicated and return a signed copy of this Letter Agreement to my attention.
Sincerely yours,
/s/ [***] | ||||||||||||||
[***] | ||||||||||||||
[***] Kaken Pharmaceutical Co., Ltd. | ||||||||||||||
Agreed this 3rd day of September, 2020. | ||||||||||||||
| /s/ Xxxx Xxxxxxx | ||||||||||||||
Name: Xxxx Xxxxxxx | ||||||||||||||
Title: Co-founder and COO | ||||||||||||||
| Brickell Biotech, Inc. | ||||||||||||||
2
SCHEDULE A
[***]
[***]
[***]
[***]
and [***] (“[***]”).
3
